Literature DB >> 17936238

Effects of sildenafil on the fetal growth of guinea pigs and their ability to survive induced intrapartum asphyxia.

Pedro Sánchez-Aparicio1, Daniel Mota-Rojas, Alejandro A Nava-Ocampo, Maria Elena Trujillo-Ortega, Alfonso Alfaro-Rodríguez, Emilio Arch, María Alonso-Spilsbury.   

Abstract

OBJECTIVE: Our goal was to determine whether sildenafil increased fetal weight and favored fetal tolerance to induced asphyxia at birth in guinea pigs. STUDY
DESIGN: Twenty guinea pigs were randomly allocated to placebo (n = 10) or sildenafil 50 microg/kg (n = 5) or 500 microg/kg (n = 5), starting from day 35 of gestation to delivery. Fetuses were delivered by cesarean section. Fetal asphyxia was induced by clamping the umbilical cord at birth for 5 minutes.
RESULTS: Sildenafil protected the pups against induced asphyxia at birth in a dose-dependent manner (eg, partial pressure (tension) of carbon dioxide levels were 75.9 +/- 19.3, 66.9 +/- 18.8, and 54.8 +/- 13.0 in the control and low- and high-dose sildenafil groups, respectively). The high-dose sildenafil group of piglets gained 1.5 times more body weight.
CONCLUSION: In guinea pigs, low doses of sildenafil administered from day 35 to the end of gestation favored fetal tolerability to induced intrapartum asphyxia. High doses of sildenafil increased fetal weight.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17936238     DOI: 10.1016/j.ajog.2007.06.068

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  7 in total

Review 1.  Pathophysiology of Perinatal Asphyxia in Humans and Animal Models.

Authors:  Daniel Mota-Rojas; Dina Villanueva-García; Alfonso Solimano; Ramon Muns; Daniel Ibarra-Ríos; Andrea Mota-Reyes
Journal:  Biomedicines       Date:  2022-02-01

2.  Guinea pig models for translation of the developmental origins of health and disease hypothesis into the clinic.

Authors:  Janna L Morrison; Kimberley J Botting; Jack R T Darby; Anna L David; Rebecca M Dyson; Kathryn L Gatford; Clint Gray; Emilio A Herrera; Jonathan J Hirst; Bona Kim; Karen L Kind; Bernardo J Krause; Stephen G Matthews; Hannah K Palliser; Timothy R H Regnault; Bryan S Richardson; Aya Sasaki; Loren P Thompson; Mary J Berry
Journal:  J Physiol       Date:  2018-05-30       Impact factor: 5.182

3.  Sildenafil therapy for fetal cardiovascular dysfunction during hypoxic development: studies in the chick embryo.

Authors:  Nozomi Itani; Katie L Skeffington; Christian Beck; Dino A Giussani
Journal:  J Physiol       Date:  2016-12-11       Impact factor: 5.182

4.  Sildenafil citrate and uteroplacental perfusion in fetal growth restriction.

Authors:  Marzieh Vahid Dastjerdi; Sayedehafagh Hosseini; Leila Bayani
Journal:  J Res Med Sci       Date:  2012-07       Impact factor: 1.852

5.  STRIDER (Sildenafil TheRapy in dismal prognosis early onset fetal growth restriction): an international consortium of randomised placebo-controlled trials.

Authors:  A Pels; L C Kenny; Z Alfirevic; P N Baker; Peter von Dadelszen; C Gluud; C T Kariya; B W Mol; A T Papageorghiou; A G van Wassenaer-Leemhuis; W Ganzevoort; K M Groom
Journal:  BMC Pregnancy Childbirth       Date:  2017-12-28       Impact factor: 3.007

6.  Detailed statistical analysis plan for the Dutch STRIDER (Sildenafil TheRapy In Dismal prognosis Early-onset fetal growth Restriction) randomised clinical trial on sildenafil versus placebo for pregnant women with severe early onset fetal growth restriction.

Authors:  Anouk Pels; Janus C Jakobsen; Wessel Ganzevoort; Christiana A Naaktgeboren; Wes Onland; Aleid G van Wassenaer-Leemhuis; Christian Gluud
Journal:  Trials       Date:  2019-01-11       Impact factor: 2.279

7.  Effects and mechanisms of action of sildenafil citrate in human chorionic arteries.

Authors:  Chrisen H Maharaj; Daniel O'Toole; Tadhg Lynch; John Carney; James Jarman; Brendan D Higgins; John J Morrison; John G Laffey
Journal:  Reprod Biol Endocrinol       Date:  2009-04-23       Impact factor: 5.211

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.